跳至主要内容
临床试验/NCT06713655
NCT06713655尚未招募不适用

Multicenter Study on PAX1 Methylation for Predicting Lesion Persistence/Recurrence in HSIL Patients with Positive Margins After Cervical Conization

Women's Hospital School Of Medicine Zhejiang University1 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2024年12月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
800
试验地点
1
主要终点
Treatment failure rate within 24 months after surgery (cervical intraepithelial neoplasia grade 2+ (CIN2+) recurrence/residual rates)

研究概览

简要总结

The goal of this multicenter, observational study is to evaluate whether methylation testing of paired box gene 1 (PAX1) can better predict and diagnose recurrence or persistent disease in patients with positive margins after cervical conization for high-grade squamous intraepithelial lesion (HSIL). The main question it aims to answer is:

Can PAX1 gene methylation testing provide a more accurate and effective prediction and diagnosis of cervical disease recurrence/persistence in addition to existing methods? Participants will be managed according to the latest clinical guidelines, and during follow-up, a non-invasive test, PAX1 gene methylation testing, will be added.

详细描述

This study is a multicenter, prospective observational study that qualitatively assesses the methylation status of the PAX1 gene in cervical exfoliated cells from patients with HSIL and positive margins after conization. The aim is to evaluate the ability of PAX1 gene methylation testing to predict treatment failure (lesion recurrence or persistence). The first follow-up occurs 6 months post-surgery, including high-risk human papillomavirus (hrHPV) testing and cytology, with referral for colposcopy, including biopsy and/or endocervical curettage (ECC), if necessary. Subsequent management and follow-up are based on examination results, following clinical guidelines, and arranged at intervals of 6-12 months depending on the findings. The follow-up includes routine clinical examinations widely applied in practice, and PAX1 testing will be completed at each follow-up visit. PAX1 testing, like hrHPV testing and cytology, will be performed using cervical exfoliated cells.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
26 Years 至 54 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age greater than 25 years and less than 55 years;
  • First-time cervical conization (cold knife conization or loop electrosurgical excision procedure);
  • Postoperative pathology showing HSIL (CIN2 or CIN3);
  • Positive margins for HSIL (CIN2 or CIN3) in conization specimen.

排除标准

  • The presence of other malignant tumors or precancerous lesions;
  • Lack of willingness for follow-up;
  • Pregnant or breastfeeding women;
  • Unable or unwilling to complete follow-up examinations;
  • History of prior cervical disease treatment (surgical or physical therapy);
  • Presence of immune system disorders.

结局指标

主要结局

Treatment failure rate within 24 months after surgery (cervical intraepithelial neoplasia grade 2+ (CIN2+) recurrence/residual rates)

时间窗: 2 years post-surgery

the percentage of HSIL treatment failure (CIN2+ recurrence and residual) within 24 months after surgery

Sensitivity of the PAX1 methylation to detect treatment failure

时间窗: 2 years post-surgery

specificity of the PAX1 methylation to detect treatment failure

时间窗: 2 years post-surgery

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Weiguo Lv

Professor

Women's Hospital School Of Medicine Zhejiang University

研究点 (1)

Loading locations...

相似试验